Related Experiment Video
Updated: Jan 12, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Association between Neutrophil-to-Lymphocyte ratio and left ventricular hypertrophy in chronic kidney disease
Li Wang1,2,3, Wen Zhang4, Jun Ji1,2,3
1Department of Nephrology, Zhongshan Hospital, Fudan University, No 180 Fenglin Rd, Shanghai, China.
Insights
Elevated neutrophil-to-lymphocyte ratio (NLR) is linked to left ventricular hypertrophy (LVH) in chronic kidney disease (CKD) patients. This inflammatory marker may help identify individuals at higher cardiovascular risk.
Area of Science:
- Cardiology
- Nephrology
- Inflammation Research
Background:
- Left ventricular hypertrophy (LVH) is a significant complication in chronic kidney disease (CKD), increasing morbidity and mortality.
- Systemic inflammation's role in LVH development within non-dialysis CKD populations requires further investigation.
- The neutrophil-to-lymphocyte ratio (NLR) is a potential, accessible marker for inflammation and predictor of LVH.
Purpose of the Study:
- To investigate the association between NLR and LVH in hospitalized CKD patients.
- To determine if NLR is an independent predictor of LVH in this population.
- To explore the mediating role of NLR in the relationship between CKD and LVH.
Main Methods:
- Cross-sectional study of 514 hospitalized CKD patients.
- LVH assessed by echocardiography (left ventricular mass index).
- NLR calculated from complete blood counts; logistic regression and mediation analyses performed.
Main Results:
- Patients with LVH exhibited significantly higher NLR levels compared to those without (3.14 vs. 2.20, p < 0.001).
- Adjusted NLR remained independently associated with LVH (adjusted OR: 1.34, 95% CI: 1.05-1.72, p = 0.02).
- NLR partially mediated the CKD-LVH relationship, accounting for 5.1% of the total effect.
Conclusions:
- Elevated NLR is independently associated with LVH in CKD patients, suggesting a role in cardiac remodeling via inflammation.
- NLR's accessibility makes it a potential marker for identifying heightened cardiovascular risk in CKD.
- Further prospective studies are needed to validate NLR as a predictive marker for LVH in CKD.
Background:
Left ventricular hypertrophy (LVH) is a common cardiovascular complication in chronic kidney disease (CKD), associated with increased morbidity and mortality. Systemic inflammation may contribute to LVH, but evidence remains limited in non-dialysis CKD populations. The neutrophil-to-lymphocyte ratio (NLR), a readily accessible inflammatory marker, may serve as a predictor of LVH.
Methods:
In this cross-sectional study, 514 hospitalized CKD patients were enrolled. LVH was defined by echocardiographic criteria based on left ventricular mass index. NLR was calculated from complete blood counts. Logistic regression models were used to evaluate the association between NLR and LVH after adjusting for potential confounders. Subgroup and restricted cubic spline (RCS) analyses were conducted to assess consistency and non-linear relationships. Mediation analysis was performed to explore whether NLR mediated the relationship between CKD and LVH.
Results:
Patients with LVH had significantly higher NLR levels than those without (3.14 vs. 2.20, p < 0.001). After full adjustment, standardized NLR remained independently associated with LVH (adjusted OR: 1.34, 95% CI: 1.05-1.72, p = 0.02). RCS showed a linear relationship between NLR and LVH risk (p for nonlinear = 0.229). Subgroup analyses confirmed this robust association across subgroups (p for interaction ≥ 0.05). Mediation analysis indicated that NLR partially mediated the relationship between CKD and LVH, accounting for 5.1% of the total effect.
Conclusion:
Elevated NLR was independently associated with LVH and may reflect underlying inflammatory processes involved in cardiac remodeling among patients with CKD. Given its simplicity and accessibility, NLR may serve as a potential marker for identifying individuals at increased cardiovascular risk, although further validation in prospective studies is warranted.
Clinical Trial Number:
Not applicable.
More Related Videos
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease IV: Nursing Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Chronic Kidney Disease I: Introduction

